Tutti gli studi
ReclutamentoFASE3INTERVENTISTICO

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

This research study is investigating an experimental medicine named eptinezumab for young people between 6 and 17 years old who experience episodic migraines. Episodic migraines mean you have them on some days, but not all the time. The main aim is to discover if eptinezumab effectively lowers the number of days these young participants suffer from migraine headaches. To find this out, some participants will receive eptinezumab, while others will get a placebo (a dummy treatment with no active medicine). This comparison helps researchers understand if any improvements are genuinely due to the study medication. This type of trial is in its third phase, meaning it's one of the final steps before a medicine might be approved for wider use.

A colpo d'occhio

Stato
Reclutamento
Fase
FASE3
Sponsor
H. Lundbeck A/S
Obiettivo di iscrizione
315
Inizio
08 Jun 2023
Completamento stimato
31 Aug 2027

Di cosa tratta questo studio?

This study is all about helping children and teenagers who get episodic migraines. Migraines aren't just bad headaches; they can be very painful and often come with other symptoms like feeling sick or being sensitive to light and sound. When we say 'episodic migraine,' it means someone has migraines on some days, but not every day.

The researchers want to test a new medicine called eptinezumab. They're hoping it can reduce how often these young people get migraines. To do this, they'll give some participants the new medicine and others a 'placebo.' A placebo looks just like the real medicine but doesn't have any active ingredients. This helps the researchers see if eptinezumab is truly making a difference, or if improvements might happen anyway.

Finding better ways to prevent migraines in young people is really important because migraines can stop them from going to school, playing with friends, and enjoying everyday activities. This study aims to find out if eptinezumab could be a safe and effective option to give them more migraine-free days.

Punti chiave

  • This study is for young people (6-17) with episodic migraines.
  • It tests a new medicine, eptinezumab, against a dummy treatment (placebo).
  • The main goal is to reduce the number of migraine days.
  • Participation involves keeping a headache diary and clinic visits.
  • You might get the active drug or a placebo.
  • Puoi lasciare lo studio in qualsiasi momento.

Chi può essere idoneo?

To join this study, children and teenagers must be between 6 and 17 years old and have been diagnosed with episodic migraines for at least six months. This means they get migraines sometimes, but not constantly. They will also need to keep a special diary on a device (eDiary) for most days during a screening period, which helps the doctors understand their migraine patterns. During this time, they should have had no more than 14 headache days in total, with at least 4 of those being actual migraine days.

There are also some reasons why someone might not be able to join. For example, if they have other serious types of headaches, certain brain or nervous system conditions, or an ongoing mental health condition that isn't under control. If they've had specific severe head injuries or certain rare migraine types, they also wouldn't be able to take part. The doctors leading the study will check all these details carefully to make sure the study is safe and appropriate for everyone involved.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Are you between 6 and 17 years old?
  2. Have you been diagnosed with migraines for at least 6 months?
  3. Do you have episodic migraines (not every day)?
  4. Can you or your caregiver use a special electronic diary to track your headaches?
  5. Do you not have other specific severe headache types or complex health issues?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

The detailed description of participation isn't fully provided in this summary, but typically, taking part in a study like this involves several visits to the clinic for check-ups and assessments. Participants would likely receive either the study medicine (eptinezumab) or the placebo. This might involve injections or infusions. They would also need to continue using the eDiary to record their migraine experiences throughout the study, helping researchers track their progress. There would be a treatment period, followed by a follow-up period to monitor their health. The total duration of participation isn't specified but usually spans several months.

Rischi e benefici potenziali

Participating in a clinical trial like this means you might benefit from a new treatment that isn't yet widely available, and you'll receive careful medical supervision. However, there's no guarantee the treatment will work for you, and like all medicines, eptinezumab could have side effects, some of which might be unknown. There's also a chance you could receive the placebo, meaning you wouldn't get the active drug. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (60)

  • New England Institute for Clinical Research (NEICR) - Stamford
    Codice postale verificato
    Stamford, United States· Reclutamento
  • Child Neurology Center (CNC) of Northwest Florida
    Codice postale verificato
    Gulf Breeze, United States· Reclutamento
  • AGA Clinical Trials
    Codice postale verificato
    Hialeah, United States· Reclutamento
  • University of South Florida (USF) - Tampa Campus
    Codice postale verificato
    Tampa, Stati Uniti· Reclutamento
  • Clinical Integrative Research Center of Atlanta (CIRCAtl)
    Codice postale verificato
    Atlanta, Stati Uniti· Completato
  • UK HealthCare-Kentucky Clinic
    Codice postale verificato
    Lexington, Stati Uniti· Completato
  • University of Maryland School of Medicine
    Codice postale verificato
    Baltimora, Stati Uniti· Completato
  • Michigan Headache & Neurological Institute (MHNI)
    Codice postale verificato
    Ann Arbor, Stati Uniti· Completato
  • True North Neurology - Commack (North Suffolk Neurology)
    Codice postale verificato
    Commack, Stati Uniti· Completato
  • OnSite Clinical Solutions, LLC - Charlotte
    Codice postale verificato
    Charlotte, Stati Uniti· Completato
  • Akron Children's Hospital
    Codice postale verificato
    Akron, United States· Reclutamento
  • Cincinnati Children's Hospital Medical Center-Burnet Campus
    Codice postale verificato
    Cincinnati, Stati Uniti· Reclutamento

Domande comuni

What is episodic migraine?

Episodic migraine means you get migraine headaches on some days, but not every day. It's different from chronic (daily) migraine.

What is eptinezumab?

Eptinezumab is a new medicine being tested to see if it can help reduce the number of migraine days for people who suffer from them.

Che cos'è un placebo?

A placebo is a 'dummy' treatment that looks just like the study medicine but doesn't contain any active ingredients. It helps researchers see if the real medicine is truly effective.

Sapró se sto ricevendo il vero medicinale o il placebo?

No, during the study, neither you nor the study doctors will know whether you are receiving eptinezumab or the placebo. This is to ensure the results are unbiased.

How old do I need to be to join?

This study is looking for children and teenagers between the ages of 6 and 17.

Come saperne di più

Email contact via H. Lundbeck A/S

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "A Study of Eptinezumab in Pediatric Participants With Episod…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.